ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Medicenna Therapeutics Corporation (QX)

Medicenna Therapeutics Corporation (QX) (MDNAF)

0.6658
0.013
(1.99%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.6658
Bid
0.60
Ask
0.7706
Volume
17,782
0.644058 Day's Range 0.66928
0.60 52 Week Range 1.94
Market Cap
Previous Close
0.6528
Open
0.65
Last Trade
300
@
0.6658
Last Trade Time
Financial Volume
$ 11,545
VWAP
0.649267
Average Volume (3m)
44,959
Shares Outstanding
78,157,903
Dividend Yield
-
PE Ratio
-2.76
Earnings Per Share (EPS)
-0.33
Revenue
-
Net Profit
-25.47M

About Medicenna Therapeutics Corporation (QX)

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Toronto, Ontario, Can
Founded
-
Medicenna Therapeutics Corporation (QX) is listed in the Biological Pds,ex Diagnstics sector of the OTCMarkets with ticker MDNAF. The last closing price for Medicenna Therapeutics (QX) was $0.65. Over the last year, Medicenna Therapeutics (QX) shares have traded in a share price range of $ 0.60 to $ 1.94.

Medicenna Therapeutics (QX) currently has 78,157,903 shares outstanding. The market capitalization of Medicenna Therapeutics (QX) is $51.02 million. Medicenna Therapeutics (QX) has a price to earnings ratio (PE ratio) of -2.76.

MDNAF Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.00681.031866464340.6590.69350.644058137980.68202679CS
4-0.1482-18.20638820640.8140.84890.632389440.71522943CS
12-0.0442-6.225352112680.710.882240.6449590.73078284CS
26-0.5642-45.86991869921.231.320.6562230.83540441CS
52-0.8442-55.90728476821.511.940.6808231.24511715CS
156-4.0042-85.74304068524.674.670.158951331.14266084CS
260-3.339-83.37495005994.00485.0420.158882511.28585733CS

MDNAF - Frequently Asked Questions (FAQ)

What is the current Medicenna Therapeutics (QX) share price?
The current share price of Medicenna Therapeutics (QX) is $ 0.6658
How many Medicenna Therapeutics (QX) shares are in issue?
Medicenna Therapeutics (QX) has 78,157,903 shares in issue
What is the market cap of Medicenna Therapeutics (QX)?
The market capitalisation of Medicenna Therapeutics (QX) is USD 51.02M
What is the 1 year trading range for Medicenna Therapeutics (QX) share price?
Medicenna Therapeutics (QX) has traded in the range of $ 0.60 to $ 1.94 during the past year
What is the PE ratio of Medicenna Therapeutics (QX)?
The price to earnings ratio of Medicenna Therapeutics (QX) is -2.76
What is the reporting currency for Medicenna Therapeutics (QX)?
Medicenna Therapeutics (QX) reports financial results in CAD
What is the latest annual profit for Medicenna Therapeutics (QX)?
The latest annual profit of Medicenna Therapeutics (QX) is CAD -25.47M
What is the registered address of Medicenna Therapeutics (QX)?
The registered address for Medicenna Therapeutics (QX) is 200 - 1920 YONGE STREET, TORONTO, ONTARIO, M4S 3E2
What is the Medicenna Therapeutics (QX) website address?
The website address for Medicenna Therapeutics (QX) is www.medicenna.com
Which industry sector does Medicenna Therapeutics (QX) operate in?
Medicenna Therapeutics (QX) operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TMSHTransGlobal Assets Inc (PK)
$ 0.0002
(19,900.00%)
322.82M
KGKGKona Gold Beverage Inc (PK)
$ 0.00014
(13,900.00%)
17.8M
GLECGlobal Ecology Corporation (CE)
$ 0.0001
(9,900.00%)
100.83k
VAXXVaxxinity Inc (CE)
$ 0.01
(9,900.00%)
206
DMKPQDMK Pharmaceuticals Corporation (CE)
$ 0.0001
(9,900.00%)
11.5k
BZAMFBZAM Ltd (CE)
$ 0.000001
(-99.99%)
4.35k
BIRMFBiorem Inc (PK)
$ 0.0011
(-99.93%)
4.95k
SBESSouth Beach Spirits Inc (CE)
$ 0.000001
(-99.50%)
4.6M
SLNAFSelina Hospitality PLC (CE)
$ 0.000001
(-99.50%)
374.46k
AAGRAfrican Agriculture Holdings Inc (CE)
$ 0.0001
(-99.33%)
786
GTCHGBT Technologies Inc (PK)
$ 0.0003
(50.00%)
1.53B
HMBLHUMBL Inc (PK)
$ 0.00025
(-16.67%)
345.25M
TMSHTransGlobal Assets Inc (PK)
$ 0.0002
(19,900.00%)
322.82M
PSWWPrincipal Solar Inc (PK)
$ 0.0004
(0.00%)
198.23M
ASIIAccredited Solutions Inc (PK)
$ 0.0002
(0.00%)
152.52M

MDNAF Discussion

View Posts
2H2 2H2 10 months ago
Big conference next week. Paris.

Oui oui!
πŸ‘οΈ0
2H2 2H2 10 months ago
Bollies on daily are tightening up kids. Big conference coming up in sept
πŸ‘οΈ0
2H2 2H2 11 months ago
Research-Capital analyst- $MDNAF buy rating & $4.5 TP

MDNA11 continue to demonstrate compelling efficacy:
2 patients #melanoma & #pancreatic treated with MDNA11 continue to demonstrate a complete response

Notably, both patients were previously treated with checkpoint inhibitors
πŸ‘οΈ0
2H2 2H2 1 year ago
And more awesome results. 20x bagger here soon? Pc needs a new top line therapy, guess who?
πŸ‘οΈ0
2H2 2H2 1 year ago
MDNAF is a presenter at ASCO. Huge news!
πŸ‘οΈ0
2H2 2H2 1 year ago
Great presentation at ASCO
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
It is what they all say about stonks trading on Cromwell Coulson’s stonk market
πŸ‘οΈ0
2H2 2H2 1 year ago
Relishing soon. This will be 10x current value this year
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
Delisted from Nasdaq
Gee, it sure is great to watch the price of a stock I bought at $400 a share advance to a 52=week high
πŸ‘οΈ0
2H2 2H2 1 year ago
Getting legs here. Train leaving.
πŸ‘οΈ0
axelvento axelvento 2 years ago
Cash runway extended through multiple data readouts and into Q1 of calendar 2025

MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively

https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-second-quarter-fiscal-2024
πŸ‘οΈ0
Renee Renee 2 years ago
MDNA changed to MDNAF. Delisted from the Nasdaq to the OTC.

https://otce.finra.org/otce/dailyList?viewType=Additions
πŸ‘οΈ0
Monksdream Monksdream 2 years ago
MDNA new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 2 years ago
MDNA new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 2 years ago
MDNA NEW 52 week low
πŸ‘οΈ0
Investopotia Investopotia 3 years ago
Medicenna Therapeutics $MDNA highlighted in Midas Letter/BioPub interview: Top Stocks to Buy Now? 3 Biotech Stocks for your Watchlist
πŸ‘οΈ0
EagleD EagleD 4 years ago
Going much higher. Double digits in a few months
πŸ‘οΈ0
EagleD EagleD 4 years ago
Nice after hours action, Just made 20,000. Yadda Yadda Yadda.

Nobody is here listening to me. THis one is going to be a beast tho
πŸ‘οΈ0
EagleD EagleD 5 years ago
FDA meeting Tuesday. Seems like we'll know sometime in October the results
πŸ‘οΈ0
EagleD EagleD 5 years ago
This is my largest holding -- ever. Lots of value to be unveiled here in the coming months.
πŸ‘οΈ0
Renee Renee 5 years ago
MDNA moved from the OTC to the Nasdaq:

https://otce.finra.org/otce/dailyList?viewType=Deletions
πŸ‘οΈ0
tykundegex tykundegex 6 years ago
Just stumbled onto this co.. was doing some research. Great interim results in their Phase2b! Encouraging grants in the past, and prestigious medical centers for their trials. I may nibble to create a starting position here.

I can't find any webinars or conf call recordings that the company has given, do you know if any exist?
πŸ‘οΈ0
BioSpecialist BioSpecialist 8 years ago
Nice move yesterday ..

Small Phase 2b trial has huge chance to be successful because it was already successfull in prior studies so this stock like to be above $10 after phase 2 results in early Q1 . And that Management holding 15+ million shares of the 24.3 million shares outstanding makes me also optimistic .GL


MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment,


Medicenna Phase 2b trial using Brainlab technology
http://www.biotuesdays.com/briefs/2017/6/8/medicenna-phase-2b-trial-using-brainlab-technology

The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the U.S.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock